SR

Subramanyam Reddy Puthana

Active Director Managing Director DIN 00268514
DIN 00268514 First appointment Dec 1994 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 3 active board seats
Past companies 2 historical roles
Total affiliations 5 Since Dec 1994
Shareholding value •••• Premium profile

About Subramanyam Reddy Puthana

Data last updated:

Subramanyam Reddy Puthana is a Managing Director at Saraca Laboratories Limited (since 1994), Director at Psr Soft Labs Private Limited (since 2006) and Designated Partner at Indus Medi Supplies Llp (since 2024). The companies operate in Pharma, Business Outsourcing and Infrastructure and Utilities. The 2 current companies with reported revenue have a combined latest revenue of ₹311 Cr; the largest is Saraca Laboratories Limited at ₹310 Cr (FY 2025). Earlier, Subramanyam Reddy Puthana was a Director at Max Infra (I) Private Limited (2009–2013) and Director at Max Infratech (India) Private Limited (P Art Ix) (from 2007).

DIN 00268514
Primary Designation Managing Director
Industry Pharma
First Appointment 16 Dec 1994
Oldest Company Age 38 yrs
Largest company Saraca Laboratories Limited · ₹310 Cr (FY 2025)
Combined revenue ₹311 Cr across 2 companies

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Saraca Laboratories Limited U85195TG1988PLC008172
Managing Director16 Dec 19941988₹310 Cr (FY 2025)Active
Psr Soft Labs Private Limited U72200TG2006PTC051113
Director12 Sep 20062006₹31.2 Lakh (FY 2025)Active
Designated Partner20 Aug 20242024Active

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Max Infra (I) Private Limited U45200TG1999PTC030861
Director24 Dec 20091999₹1,489 Cr (FY 2024)Active
Director25 Sep 20072007Amalgamated

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Psr Soft Labs Private Limited
Max Infratech (India) Private Limited (P Art Ix)
Saraca Laboratories Limited
Indus Medi Supplies Llp
Premium access

Shareholding and investment profile for Subramanyam Reddy Puthana

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Subramanyam Reddy Puthana

Subramanyam Reddy Puthana currently holds 3 directorships: Saraca Laboratories Limited (Managing Director, since 16 Dec 1994, revenue ₹310 Cr (FY 2025)); Psr Soft Labs Private Limited (Director, since 12 Sep 2006, revenue ₹31.2 Lakh (FY 2025)); Indus Medi Supplies Llp (Designated Partner, since 20 Aug 2024).

Subramanyam Reddy Puthana was first appointed on 16 Dec 1994 as Managing Director at Saraca Laboratories Limited. The most recent appointment on record is 20 Aug 2024 at Indus Medi Supplies Llp.

The 2 current companies of Subramanyam Reddy Puthana that report revenue have a combined latest revenue of ₹311 Cr: Saraca Laboratories Limited ₹310 Cr (FY 2025); Psr Soft Labs Private Limited ₹31.2 Lakh (FY 2025).

Subramanyam Reddy Puthana held 2 earlier board appointments: Max Infra (I) Private Limited (Director, 24 Dec 2009 to 18 Oct 2013); Max Infratech (India) Private Limited (P Art Ix) (Director, from 25 Sep 2007).

The current boards of Subramanyam Reddy Puthana's companies include Gargi Pammi (Saraca Laboratories Limited), Hemanth Nandigala (Saraca Laboratories Limited), Lingareddy Subba Reddy Venkata (Saraca Laboratories Limited), Mundla Maha Vishnu (Saraca Laboratories Limited), Prasanth Nandigala (Saraca Laboratories Limited), Shailesh Shivappa Biradar (Saraca Laboratories Limited), among others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available